Tc-99m-MIBI scintimammography; SPECT versus planar imaging

Area of Science:

• Nuclear Medicine
• Radiopharmaceuticals
• Diagnostic Imaging

Background:

• Planar scintimammography is a diagnostic tool for breast lesion evaluation.
• Tc99m-sestamibi (MIBI) is a radiopharmaceutical used in nuclear imaging.
• Comparison between planar scintimammography and SPECT is crucial for optimizing breast cancer detection.

Purpose of the Study:

• To compare the diagnostic performance of single photon emission tomography (SPECT) with planar scintimammography.
• To evaluate the efficacy of Tc99m-sestamibi (MIBI) uptake visualization in differentiating benign from malignant breast lesions.
• To assess improvements in sensitivity, specificity, and predictive values using SPECT compared to planar imaging.

Main Methods:

• A study involving 150 lesions (16 normal, 54 benign, 80 malignant) was conducted.
• Patients received 700 MBq of Tc99m-sestamibi intravenously, followed by planar and SPECT imaging.
• A scoring system was used to quantify MIBI uptake, with results compared between imaging modalities.

Main Results:

• SPECT imaging missed fewer malignant lesions (4) compared to planar imaging (10).
• SPECT demonstrated significantly higher sensitivity (95% vs. 87.5%) and negative predictive value (93.7% vs. 85.7%) than planar imaging.
• While specificity and positive predictive values were similar, SPECT provided a significant increase in score for the malignant group.

Conclusions:

• Tc99m-sestamibi SPECT scintimammography significantly enhances diagnostic accuracy over planar imaging for breast lesions.
• The improved sensitivity and negative predictive value of SPECT allow for more confident exclusion of malignancy.
• SPECT imaging is recommended for further evaluation, especially when MIBI uptake is absent, to rule out cancer.